deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT00086411

Comparing Smoking Treatment Programs for Lighter Smokers - 1

Comparing Smoking Treatment Programs for Lighter Smokers

Sponsor: National Institute on Drug Abuse (NIDA)

Updated 10 times since 2017 Last updated: Jul 25, 2019 Started: Sep 30, 2003 Primary completion: Apr 30, 2008 Completion: Jun 30, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00086411, this PHASE2 trial focuses on Tobacco Use Disorder and remains completed. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 10 times since 2003, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

The study compared a minimal level counseling model to a higher level counseling model plus one of two types of FDA approved smoking cessation products (bupropion or the nicotine patch)used to achieve long term abstinence among lighter smokers. Each participant received both products under blinded conditions meaning that neither the participant nor the counselor knew which product was real or a placebo. The primary goal was to determine the combination or combinations of high or low intensity counseling and pharmacotherapy (either bupropion or the nicotine patch) that were most effective for lighter smokers. The main hypothesis was that higher level counseling would contribute to improved outcomes meaning that more counseling would be associated higher abstinence rates following the completion of treatment and at longer term follow-up.

The study compared a minimal level counseling model to a higher level counseling model plus one of two types of FDA approved smoking cessation products (bupropion or the nicotine patch)used to achieve long term abstinence among lighter smokers. Each participant received both products under blinded conditions meaning that neither the participant nor the counselor knew which product was real or a placebo. The primary goal was to determine the combination or combinations of high or low intensity counseling and pharmacotherapy (either bupropion or the nicotine patch) that were most effective for lighter smokers. The main hypothesis was that higher level counseling would contribute to improved outcomes meaning that more counseling would be associated higher abstinence rates following the completion of treatment and at longer term follow-up.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotCompleted~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshotCompleted~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

10 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Present [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

Show 5 earlier versions
  1. Sep 2019 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2019 — Sep 2019 [monthly]

    Completed PHASE2

  3. Jun 2018 — Jun 2019 [monthly]

    Completed PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute on Drug Abuse (NIDA)
  • University of Pennsylvania
Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations